(Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device

Purpose: Radiopaque gold markers can be implanted in the prostate to visualize its position on portal images during radiation therapy. This procedure assumes that the markers do not move within the prostate. In this work we test this assumptiom. Methods and Materials: Three markers were implanted transrectally in the prostate of patients undergoing external radiation therapy. An orthogonal pair of portal images was acquired periodically throughout the course of radiation therapy with an a-Si electronic portal imaging device (EPID). The marker coordinates were determined, and the distances between the implanted markers were recorded. The distance time trend is used to evaluate the magnitude of marker migration. Results: The average standard deviation (SD) of the distances between markers was 1.3 mm (range 0.44 to 3.04 mm). Three of the 11 patients show a SD larger than 2 mm. For these patients, all three distances show a simultaneous reduction with time, compatible with a shrinking of the prostate. All had been treated with neoadjuvant hormone therapy. For 1 of the 3 patients, this reduction in volume was confirmed with a repeat computed tomographic scan. Conclusion: None of the 33 markers studied migrated significantly. The implantation of three radiopaque gold markers enables accurate and precise on-line verification of the prostate position during external beam radiation therapy. The use of three markers provides a tool to monitor prostate position and volume changes that can occur over time due to hormone or radiation therapy. (C) 2003 Elsevier Inc.